Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | UGCG | Q16739 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321718 | 0.92 | SCN9A (0.54) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL13754838 | 0.87 | SCN9A (0.47) | SCN9ACYP2C9CYP3A4CYP2D6UGCG | |
| SCHEMBL1400166 | 0.86 | SCN9A (0.65) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4320064 | 0.84 | PTGER1 (0.55) | CYP2C9FEN1 | |
| SCHEMBL4329018 | 0.84 | PTGER1 (0.47) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL1400056 | 0.83 | SCN9A (0.60) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL4325194 | 0.83 | SCN9A (0.61) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL4327295 | 0.83 | PTGER1 (0.43) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL13913159 | 0.82 | SCN9A (0.48) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL4488075 | 0.82 | SCN9A (0.62) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | SCN9A 56/4885CYP2C9 349/4885CYP3A4 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.